Bennett KK, De Gruttola V, Marschner, IC, Havlir DV, Richman DD. Baseline predictors of CD4 T lymphocyte recovery with combination antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 2002; 31(1):20-26.

Gilbert PB, De Gruttola V, Hudgens MG, Self SG, Hammer SM, Corey L. What constitutes efficacy for a HIV vaccine that ameliorates viremia: Issues involving surrogate endpoints in Phase 3 trials. Journal of Infectious Diseases, 2003; 188(2):179-93.

DiRienzo AG and De Gruttola V. Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clinical Trials Group Study A5142. Control Clin Trials, 2003; 24(2):122-34.

Foulkes AS and De Gruttola V. Characterizing classes of antiretroviral drugs by genotype. Statistics in Medicine, 2003; 22(16):2637-2655.

DiRienzo AG, De Gruttola V, Larder B, Hertogs K. Nonparametric Methods to predict HIV drug susceptibility phenotype from genotype. Statistics in Medicine, 2003; 22(17):2785-2798.

Brown ER, Ibrahim JG, Degruttola V. A flexible B-spline model for multiple longitudinal biomarkers and survival. Biometrics, 2005; 61(1):64-73.